Updated:
Hibiscus BioVentures
Hibiscus BioVentures is a Rockville-based private equity firm investing in early-stage biotechnology and life sciences companies near the NIH.
Hibiscus BioVentures
Hibiscus BioVentures is a venture studio founded in 2019 in Rockville, Maryland. The company was formerly known as Orchid BioVentures. It operates a venture capital arm that invests in biotechnology companies, including AsclepiX Therapeutics in a Series A - II investment on July 26, 2023. Hibiscus BioVentures has made 2 investments.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rockville
Corporate office
Rockville, MD, United States
Sector focus
Frequently asked questions
What is Hibiscus BioVentures' investment focus?
The firm targets early-stage and expansion-stage investments in biotechnology, medical devices, and life sciences tools. Its mandate emphasizes capital-efficient therapeutics and platform technology companies, often before they reach revenue or pivotal clinical data.
Where does Hibiscus BioVentures source its deals?
Proximity to the National Institutes of Health, Johns Hopkins University, and the Maryland biotech corridor is central to its sourcing model. The firm is positioned to access investigator-led spinouts and early licensing opportunities emerging from these public research institutions.
Does Hibiscus BioVentures invest via funds or direct deals?
Available public records indicate the firm makes direct investments into life sciences companies. There is no evidence of a fund-of-funds approach or participation in external venture funds as a limited partner.
Who are the principals leading Hibiscus BioVentures?
Named principals and the investment team structure are not publicly disclosed in the sources consulted. The firm maintains a low profile, typical of a boutique life sciences investor without active press outreach.
How large is Hibiscus BioVentures by assets under management?
AUM is not publicly disclosed. No regulatory filings or press reports specifying fund size or total capital deployment were located. The firm's AUM status is therefore listed as undisclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: